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The presence of four lysosomal storage diseases (LSDs) at increased frequency in the Ashkenazi Jewish population
has suggested to many the operation of natural selection (carrier advantage) as the driving force. We compare LSDs
and nonlysosomal storage diseases (NLSDs) in terms of the number of mutations, allele-frequency distributions,
and estimated coalescence dates of mutations. We also provide new data on the European geographic distribution,
in the Ashkenazi population, of seven LSD and seven NLSD mutations. No differences in any of the distributions
were observed between LSDs and NLSDs. Furthermore, no regular pattern of geographic distribution was observed
for LSD versus NLSD mutations—with some being more common in central Europe and others being more common
in eastern Europe, within each group. The most striking disparate pattern was the geographic distribution of the
two primary Tay-Sachs disease mutations, with the first being more common in central Europe (and likely older)
and the second being exclusive to eastern Europe (primarily Lithuania and Russia) (and likely much younger). The
latter demonstrates a pattern similar to two other recently arisen Lithuanian mutations, those for torsion dystonia
and familial hypercholesterolemia. These observations provide compelling support for random genetic drift (chance
founder effects, one ∼11 centuries ago that affected all Ashkenazim and another ∼5 centuries ago that affected
Lithuanians), rather than selection, as the primary determinant of disease mutations in the Ashkenazi population.
Introduction
The Ashkenazi Jewish (AJ) population is subject to a
variety of genetic diseases (Goodman 1979), primarily
owing to historical founder effects that have occurred
in the Jewish population over the past two millennia.
Much attention originally focused on lysosomal storage
diseases (LSDs), four of which—Tay-Sachs disease (TSD
[MIM 272800]), Gaucher disease (GD [MIM 230800]),
Niemann-Pick disease (NPD [MIM 257200]), and muco-
lipidosis type IV (MLIV [MIM 252650])—occur at in-
creased frequency in the AJ population (Goodman and
Motulsky 1979). However, it has also become apparent
that mutations for numerous other types of genetic disor-
ders (nonlysosomal storage diseases [NLSDs]) also occur
in this population at increased frequency, including Bloom
syndrome (BLM [MIM 210900]), Fanconi anemia type
C (FACC [MIM 227645]), Canavan disease (CAN [MIM
271900]), familial dysautonomia (DYS [MIM 223900]),
factor XI deficiency (F11 [MIM 264900]), familial hy-
perinsulinism (HI [MIM 256450]), familial hypercholes-
terolemia (FH [MIM 143890]), cystinuria (CSNU [MIM
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220100]), familial neurosensory deafness (NSRD1 [MIM
220290]) due to connexin 26 (CX26 [MIM 121011]),
glycogen storage disease type VII (GLY7 [MIM 232800]),
and torsion dystonia (DYT1 [MIM 128100]), among oth-
ers (Goodman and Motulsky 1979; Motulsky 1995).
Over the past decade, developments in molecular bi-
ology have allowed for the identification of the specific
mutations underlying most of these disorders. Typical-
ly, multiple different mutations have been identified for
each, although, in most cases, it is a single mutation that
appears to predominate.
The anomalous presence of four different LSDs in
the AJ population has been the source of long-standing
controversy. Many have argued that the low likelihood
of four such diseases—particularly when all four are in-
volved in the storage of glycosphingolipids—must reflect
past selective advantage for heterozygous carriers of these
conditions (Myrianthopoulos and Aronson 1966; Chak-
ravarti and Chakraborty 1978; Motulsky 1979; Yoko-
yama 1979; Rotter and Diamond 1987; Zlotogora et al.
1988; Jorde 1992; Beutler et al. 1993; Diamond 1994;
Boas 2000), whereas others have argued for the predom-
inant role of genetic drift and founder effects (Chase and
McKusick 1972; Rao and Morton 1973; Fraikor 1977;
Wagener et al. 1978; Cavalli-Sforza 1979; Risch et al.
1995).
The large number of mutations that have been found,
in the AJ population, for LSDs has provided some with
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an argument in favor of the selection hypothesis (Dia-
mond 1994). In particular, statistical analyses have been
presented, to confirm the low probability of seeing mul-
tiple different mutations for the same disease at increased
frequency (Jorde 1992). If selection was the driving force,
however, questions remain as to the timing, location, and
agent of such selection.
With advances in molecular genetics and large-scale
screening, the opportunity to provide further evidence
regarding these alternative hypotheses now presents
itself. The AJ population is subject to a variety of
different inherited medical conditions, including can-
cers, blood diseases, biochemical disorders, and neu-
ropathies, in addition to the LSDs. It is unlikely that
all these conditions have been the subject of carrier
selective advantage (especially the dominant condi-
tions—e.g., DYT1, breast cancer, and FH) or at least
the subject of the same selective forces, should they
exist. Thus, it is informative to compare mutations for
the LSDs and NLSDs in several respects, to see if dif-
ferences exist. In particular, we contrast (1) the number
and frequency of mutations for the LSDs and NLSDs;
(2) the estimated coalescence times for various muta-
tions obtained, through haplotype analysis (Risch et al.
1995), from LSDs and NLSDs; and (3) the geographic
distribution in Europe—in particular, central Europe
(CE) versus eastern Europe (EE)—for LSD versus NLSD
mutation frequencies. Clear differences in the above dis-
tributions between LSDs and NLSDs would support the
hypothesis that special selective forces have operated on
the former. By contrast, lack of differences between them
supports genetic drift as the primary force.
Material and Methods
Analysis of Mutation Frequencies
The published literature was scanned for disease mu-
tations found in the AJ population, and allele frequencies
were extracted. For multiple reports of the same mu-
tation, an overall allele frequency was obtained by com-
bining the estimates weighted by sample size. A list of
the diseases and mutations included in this analysis are
given in appendix A (see table A1).
Analysis of Mutation Ages
Estimates for coalescence times for various muta-
tions were obtained from published reports when avail-
able. Coalescence dates not previously published but
for which haplotype data were available for such esti-
mation were derived from published haplotype data by
use of previously derived formulas (Risch et al. 1995;
Goldstein et al. 1999).
Analysis of Geographic Distributions
Analysis of geographic distributions of mutation fre-
quencies was based on new data derived from the Dor
Yeshorim genetic-testing program (see Broide et al. 1993).
Study subjects.—Study subjects were generally high-
school-age students from the Orthodox Jewish commu-
nity who agreed to anonymous testing for recessive dis-
ease mutations found at increased frequency in the AJ
population. Most subjects were self-identified as AJ. All
subjects were questioned about country or region of origin
of all four grandparents. Approximately 2% of grand-
parents were identified as Jews of either Sephardic or
Asian origin. Informed consent forms were received ei-
ther from study subjects or from the parents of minors.
The number of subjects tested varies depending on the
date when analysis of the disease in question was ini-
tiated—1992 (for TSD and GD), 1993 (for CF), 1995
(for FACC), or 2000 (for BLM and NPD). Because of
uncertain counseling for homozygotes for the most com-
mon GD mutation (1226G), GD testing was limited to
an initial pilot screening project plus subjects requesting
this test.
Dor Yeshorim maintains two intake centers, one in
Brooklyn, NY, and the other in Jerusalem. Approxi-
mately 45% of subjects were from the New York met-
ropolitan area, and 5% were from the rest of North
America; for these subjects, blood samples were drawn
and were delivered to the Brooklyn site. Another 45%
of subjects were from Israel, and another 5% were from
Europe; blood samples from these subjects were sent
to the center in Israel.
DNA analysis.—Coded and anonymized blood sam-
ples were sent from the two Dor Yeshorim intake cen-
ters, in New York and Israel, to various laboratories for
DNA analysis. Mutation testing was performed for sev-
en recessive diseases and 14 mutations, by 12 indepen-
dent quality-controlled laboratories: Mt. Sinai School of
Medicine (New York); Albert Einstein College of Med-
icine (Bronx, NY); Baylor College of Medicine Kleeberg
DNA Laboratory (Houston); University of Pittsburgh
(Pittsburgh); Kingsbrook Jewish Medical Center (Brook-
lyn, NY); New York University (New York); Hadassah
Hebrew University Hospital (Jerusalem); National Hos-
pital, Institute of Neurology (London); Thomas Jeffer-
son Hospital (Philadelphia); Scripps Research Labora-
tory (San Diego, CA); Integrated Genetics (Framingham,
MA); and Rockefeller University (New York). Different
laboratories tested different mutations, and several lab-
oratories received aliquots from the same individual for
testing. Results from participating laboratories were en-
tered into a secured computer file by identification num-
ber. Double data entry was employed, to eliminate data-
entry errors. Random control samples were included in
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Table 1
Ordered Mutation Frequencies for LSDs and NLSDs in the Ashkenazi Population—Data from the Literature
Disease/Locus (Mutation) Frequency Reference(s)
LSDs:
GD (1226) .032 Beutler et al. 1993
TSD (1277) .013 Paw et al. 1990; Triggs-Raine et al. 1990; Grebner and Tomczak 1991
NPD (1302) .005 Caganna et al. 1994
MLIV (IVS3) .004 Bargal et al. 2001; Edelmann 2002
TSD (1421) .003 Paw et al. 1990; Triggs-Raine et al. 1990; Grebner and Tomczak 1991
GD (84GG) .002 Beutler et al. 1993
Other diseases:
APC (I1307K) .035 Laken et al. 1997; Woodage et al. 1998; Rozen et al. 1999; Drucker et al. 2000
F11 (type III) .025 Shpilberg et al. 1995
F11 (type II) .022 Shpilberg et al. 1995
CX26 (167delT) .020 Morrell et al. 1998; Dong et al. 2001
DYS (IVS20) .016 Dong et al. 2002
CAN (854) .012 Kronn et al. 1995; Matalon et al. 1995
CSNU (808CrT) .008 Pras et al. 1995
CF (1282) .008 Kerem et al. 1995
FACC (IVS4) .006 Verlander et al. 1995; Peleg et al. 2002
BRCA1a (185delAG) .006 Roa et al. 1997; Streuwing et al. 1997
BRCA2a (6174delT) .006 Oddoux et al. 1997; Roa et al. 1997; Streuwing et al. 1997
HI (3992) .006 Nestorowicz et al. 1996
BLM (2281) .005 Shahrabani-Gargir et al. 1998; Peleg et al. 2002
CF (F508) .005 Kerem et al. 1995
CX26 (35delG) .004 Morrell et al. 1998; Dong et al. 2001
FHa (G197del) .003 Meiner et al. 1991
CAN (693) .002 Kronn et al. 1995; Matalon et al. 1995
GLY7 (del5) .002 Sherman et al. 1994
a Autosomal dominant mutations; all others are autosomal recessive.
most shipments of samples to each laboratory, to eval-
uate and rectify any laboratory genotyping problems.
Definition of geographic ancestry.—Grandparents
were classified into 12 country/region-of-origin cate-
gories, on the basis of sufficient numbers of subjects.
These included the countries of Austria, Czechoslova-
kia, Germany, Hungary, Lithuania, Poland, Romania,
and Russia. Grandparents from Galicia were included
as Polish, and those from the Ukraine were included
as Russian. Grandparents from South Africa were in-
cluded as Lithuanian, since South African Jews are
primarily of Lithuanian origin (Meiner et al. 1991).
It must be recognized that these categories are only
approximate, since national/regional borders have shift-
ed during the past century. Because of small numbers,
Sephardic and North African Jews were combined in-
to a single category, designated as “Mediterranean,”
which included all North African countries plus Spain,
Portugal, Gibraltar, Greece, Cyprus, Rhodes, Turkey,
and Italy. Another combined group, designated as
“Mideast,” included those from all countries in the
Middle East, India, and southern republics of the for-
mer Soviet Union (Georgia, Azerbaijan, Kazakhstan,
Armenia, Dagestan, and Uzbekistan).
A mixed, primarily Ashkenazi group, designated as
“mixed AJ,” was defined on the basis of other coun-
tries of origin with mostly Ashkenazi representation
(the United States, Canada, Australia, the United King-
dom, other countries of western Europe, Switzerland,
and Latin America). Finally, those with no known coun-
try or region of origin were included in the category
designated as “unknown.”
Several prior studies have shown a northeastern–south-
central cline, in Europe, of allele frequencies for some
Ashkenazi diseases and mutations (Petersen et al. 1983;
Meiner et al. 1991; Peleg et al. 1994; Risch et al. 1995;
Shahrabani-Gargir et al. 1998). Accordingly, we also
created a category designated as “CE,” composed of
Austria, Czechoslovakia, Hungary, and Romania, and
a category designated as “EE,” composed of Poland,
Russia, and Lithuania. The former group is primarily
Hungarian, and the latter group is primarily Polish.
Germany was not included in the CE category, because
a prior study of TSD (Petersen et al. 1983) suggested
that Germany is more typical of EE countries, possibly
owing to migrations from EE in modern times.
Statistical analysis.—To extract the maximum amount
of information from our data, we estimated mutation
frequencies by country/region of origin through use of
maximum likelihood and tested for differences between
countries/regions through use of likelihood-ratio tests.
The probability model is as follows: For I countries/
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Table 2
Estimated Coalescence Times of Various Mutations
Disease/Locus
(Mutation) Generations Reference
LSDs:
GD (1226) 48 Diaz et al. 2000
MLIV (IVS3) 57 Slaugenhaupt et al. 1999
GD (84GG) 55 Diaz et al. 2000
Other diseases:
F11 (type III) 31 Goldstein et al. 1999
F11 (type II) 120 Goldstein et al. 2000
DYS (IVS20) 52 Blumenfeld et al. 1993
BLM (2281) 50 Ellis et al. 1998
BRCA1a (185delAG) 46 Neuhausen et al. 1996
BRCA2a (6174delT) 29 Neuhausen et al. 1996
FHa (G197del) 12 Durst et al. 2001
DYT1 (delGAG) 12 Risch et al. 1995
a Autosomal dominant mutations; all others are autosomal recessive.
regions, we define I parameters , , withp ip 1, … , I pi i
representing the allele frequency for a given mutation in
the ith country/region. The probability p that an indi-
vidual is a carrier is a linear combination of the valuespi
based on the individual’s four grandparents. For exam-
ple, if the four grandparents are from categories 2, 4, 5,
and 2, then . For I countries of or-pp p  (p  p )/22 4 5
igin, there are Ap I 3I(I 1)/2 I(I 1)(I 2)/2
I(I 1)(I 2)(I 3)/24 possible country/region-of-ances-
try combinations for four grandparents. The four terms
in A, above, correspond to the number of combinations
involving 1, 2, 3, or 4 countries/regions, respectively. In
our case, for , ; for , .Ip 12 Ap 1,365 Ip 7 Ap 210
We enumerate each possible ancestry combination by use
of the subscript letter “a,” . The carrier prob-ap 1, … , A
ability for ancestry combination a is denoted .pa
The data consist of a set of variables and ,N Ya a
, where is the total number of individualsap 1, … , A Na
with ancestry combination a and is the number ofYa
such individuals who are mutation carriers. As a close
approximation to the binomial, we model the carrier
counts by a Poisson distribution with mean . TheY N pa a a
log likelihood for the data , aside from a constant, isYa
given by
ln Lp  N p  Y ln p , (1) a a a a
where each is a different linear combination of thep pa i
values. The maximum of as a function of the valuesln L pi
and the corresponding maximum-likelihood estimates of
the values were obtained using Matlab (Mathworks).pi
Differences between CE and EE were tested as follows:
First, the seven-parameter model, allowing separate es-
timates for CE and EE, was fit, and log likelihood (eq.
[1]) was estimated. Two of the parameters were for the
CE frequency and the EE frequency; the remaining five
parameters represented the allele frequency for the un-
known, mixed AJ, German, Mediterranean, and Mideast
groups. Next, a six-parameter model—allowing a single
estimate for CE and EE combined, along with the other
five frequencies described above—was fit, and equation
(1) was reestimated. Twice the difference in log likeli-
hood was assumed to have a x2 distribution with 1 df.
Because genetic testing at Dor Yeshorim is anonymized,
it is impossible to determine relatedness of study subjects.
It is likely that some related individuals are included in
the database, and, thus, their carrier status should not
technically be considered to be statistically independent.
The most serious potential violation of independence is
likely to occur through sibships in which more than one
sib from the same family has been tested. To assess the
potential impact that such nonindependence has on our
statistical analyses, we consider the following model. Sup-
pose that there are a total of N families, each with s sibs
tested. Let be 1 if the jth sib in the ith family is aXij
carrier and 0 otherwise. Then, the allele-frequency esti-
mate is given by
N s1′p p X , ij2T ip1 jp1
where . The variance of p′ is given byTp 2Ns
1′ [ ]Var (p )p 2p (s 1)p ,2T
where the first term corresponds to the individual variance
for each sib and the second term corresponds to the co-
variance (nonindependence effect) for multiple sibs. Here,
we ignore terms with higher orders of p, assuming that
p is small. Then, the information ratio (inverse of vari-
ance), defined as the actual information divided by the
information obtained assuming that sibs are independent,
is given by . If we assume (very conservatively)2/(s 1)
that the sample contains families with three tested sibs,
then the information ratio is 2. Thus, a conservative ad-
justment to our statistical (x2) tests would be to divide
the obtained x2 values by 2.
Results
Mutation Frequencies
Table 1 presents mutations for LSDs and NLSDs in
descending order of frequency, summarized from the lit-
erature. There are no striking differences in terms of the
number of mutations or their frequencies between the two
groups. The highest frequency among LSDs, 0.032 (for
the GD 1226G mutation), is similar to the adenomatous
polyposis coli (APC [175100]) I1307K mutation. Both of
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Table 3
Number of Grandparents, as Reported by Tested Individuals, by Country/Region of Origin and Disease Tested
NO. OF GRANDPARENTS OF INDIVIDUALS WITH
BLM CAN CF FACC GDa NPD TSD
Unknown 9,749 122,506 142,978 111,610 63,197 7,183 100,293
Mixed AJb 2,966 41,784 49,777 34,499 15,668 2,318 29,485
Germany 1,000 9,867 10,750 9,635 4,615 752 29,485
CE: 6,554 62,358 68,221 60,992 32,898 4,910 55,875
Austria 301 3,066 3,384 3,007 1,583 225 2,783
Czech 715 7,283 8,008 7,154 4,073 545 6,437
Hungary 4,255 39,666 43,076 39,052 21,269 3,171 35,945
Romania 1,283 12,343 13,753 11,779 5,973 969 10,710
EE: 6,086 55,651 59,429 54,778 26,008 4,514 50,027
Lithuania 488 4,027 4,225 3,988 1,552 409 3,718
Polandc 3,790 35,761 38,199 35,307 16,958 2,784 32,328
Russiad 1,808 15,862 17,004 15,482 7,498 1,321 13,980
Mediterraneane 839 3,611 4,088 3,320 1,953 703 2,941
Mideastf 558 2,219 2,441 2,098 1,197 504 1,896
Total 27,752 297,996 337,684 276,932 145,536 20,884 249,372
a Only 48% were tested for the 1604 mutation.
b Includes the United States, Canada, Australia, the United Kingdom, western Europe, Switzerland, and Latin
America.
c Includes Galicia.
d Includes Ukraine.
e Includes North Africa, Spain, Portugal, Gibraltar, Greece, Cyprus, Rhodes, Turkey, and Italy.
f Includes Middle East countries, India, Georgia, Azerbaijan, Kazakhstan, Armenia, Dagestan, and Uzbekistan.
these mutations have low penetrance and are generally
nonlethal. Although TSD and GD both have second mu-
tations with frequency 10.002, the same is true for breast
cancer, CAN, F11, NSRD1 due to CX26, and CF.
Ages of Mutations
Table 2 contains the coalescence times (in generations)
for LSD and NLSD mutations reported in the literature,
for GD (Diaz et al. 2000), F11 (Goldstein et al. 1999),
DYT1 (Risch et al. 1995), BRCA1 (Neuhausen et al.
1996), BRCA2 (Neuhausen et al. 1998), and FH (Durst
et al. 2001). Times for other mutations were obtained
from published haplotype data and were estimated by
use of published formulas (Risch et al. 1995; Goldstein
et al. 1999): BLM (Ellis et al. 1998), MLIV (Slaugen-
haupt et al. 1999), and DYS (Blumenfeld et al. 1993).
The numbers of generations fall approximately into
three founder-event categories: 1100 generations (found-
ing and expansion of the Jewish population in the Mid-
dle East), 50 generations (founding and expansion of
Ashkenazi Jews in CE), and 12 generations (founding
and expansion of Lithuanian Jews). Although some mu-
tations of the first two groups are found in non-Ash-
kenazi Jews—in particular, F11 type II (Peretz et al.
1997) and BRCA1 185delAG (Bar-Sade et al. 1997,
1998)—others are restricted primarily to Ashkenazim.
The two recent mutations (in DYT1 and FH) are specific
to Lithuanian Jews (Meiner et al. 1991; Risch et al.
1995). The three LSD mutations date approximately
to the founding of the Ashkenazim, as do most of the
NLSD mutations.
Geographic Distribution of Mutations
Here, we present new data on the geographic distribu-
tion of 14 mutations for seven diseases, three of which
(GD, NPD, and TSD) are LSDs and four of which (BLM,
CAN, CF, and FACC) are not. These data derive from
the Dor Yeshorim carrier-testing program, initiated in
Brooklyn, NY, in 1983, with the purpose of testing mar-
riage-age individuals from the Orthodox Ashkenazi com-
munity (Broide et al. 1993). The original program was
based on enzyme testing for TSD. In 1992, mutation test-
ing was initiated. Since that time, mutation testing for the
six other diseases listed above has been introduced (see
the “Material and Methods” section). Study subjects were
queried regarding country/region of origin of each of their
four grandparents. These responses were condensed into
12 different geographic categories and were used for mu-
tation-frequency estimation by maximum likelihood (see
the “Material and Methods” section).
The number of grandparents that study subjects iden-
tified by geographic region for each of these seven diseases
is given in table 3. The number of subjects tested is one-
fourth the total number of grandparents listed in the bot-
tom of the table and varies by year of introduction of the
test. Thus, the numbers range from 5,221 subjects tested
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Table 4
Mutation Frequencies for LSDs, by Geographic Region
FREQUENCY OF MUTATION IN
GD NPD TSD
1226 1604 84GG L302 1277 1421 G269
Unknown .0371 .0026 .0053 .0031 .0190 .0009 .0007
Mixed AJ .0284 .0033 .0016 0 .0145 .0041 .0013
Germany .0367 .0040 .0080 0 .0173 .0019 .0006
CE: .0382 .0023 .0050 .0036 .0218 0 .0003
Austria .0163 .0047 .0027 0 .0464 0 .0058
Czech .0381 0 .0034 0 .0283 0 0
Hungary .0356 .0023 .0046 .0058 .0198 0 0
Romania .0528 .0033 .0101 0 .0190 0 0
EE: .0303 .0032 .0006 .0010 .0175 .0041 .0010
Lithuania .0322 0 0 0 .0211 .0113 .0022
Poland .0311 .0043 .0010 .0016 .0171 .0022 .0013
Russia .0287 .0018 .0001 0 .0168 .0067 0
Mediterranean .0028 .0006 0 0 0 0 0
Mideast 0 0 0 0 0 .0005 0
RESULT FOR MUTATION IN
GD NPD TSD
1226 1604 84GG L302 1277 1421 G269
x2 (CE vs. EE) 6.6** .5 28.5*** 2.8 6.1* 89.2*** 3.7
No. of carriers 2,504 93 289 22 2,289 215 88
* .P ! .05
** .P ! .01
*** .7P ! 10
for NPD to 84,421 subjects tested for CF. The numbers
of grandparents listed may include the same individual
counted more than once, because there is the possibility
that related individuals (e.g., sibs) were included in the
database (see the “Material and Methods” section). As
can be seen in table 3, ∼41% of grandparents are of
unknown origin, and 13% are classified as mixed AJ.
Among the remainder, the highest percentages are for
Hungary (14%) and Poland (12%), followed by Russia
(5%), Romania (4%), Germany (3%), Czechoslovakia
(3%), Lithuania (1%), and Austria (1%). Mediterranean
and Mideast grandparents each constitute ∼1% of the
sample. Because of the particular Orthodox groups in-
cluded in this testing program, a higher proportion derives
from CE (Hungary) than is true for other Ashkenazi sam-
ples (Petersen et al. 1983).
A total of 14 different mutations for seven diseases
were studied: BLM (2281), CAN (693 and 854), CF
(1282, F508, and 542), FACC (IVS4), GD (1226G,
1604, and 84GG), NPD (1302), and TSD (1277, 1421,
and G269). Frequencies for the seven LSD mutations
obtained from maximum-likelihood estimation (see the
“Material and Methods” section) are given in table 4,
and those for the seven NLSD mutations are given in
table 5. The individual countries that constitute the CE
and EE categories are listen in the tables, beneath those
for the combined categories. The bottom row provides
the total number of mutation carriers observed among
all tested subjects. For the LSDs, four mutations are
more common in CE, and three are more common in
EE; four of these differences reached statistical signifi-
cance. Because of the possibility that related individuals
were included in the database, the two x2 values, 6.1
and 6.6, should be considered as suggestive (see the
“Material and Methods” section). The others are clearly
significant. Similar to the results of Petersen et al. (1983)
for enzyme detected carriers, the primary TSD mutation
1277 has a higher frequency in CE versus EE. The same
is true for the first (1226G) and, especially, the second
(84GG) most common mutations in GD. By contrast,
the two less frequent TSD mutations were each more
common in EE, especially the 1421 variant.
The pattern for the NLSDs is similar. Among the six
mutations for which a difference exists, four have higher
frequency in CE, and two have higher frequency in EE.
Among the three with differences that are statistically
significant, two (CAN 693 and CF F508) are more com-
mon in CE, and one (BLM 2281) is more common in
EE. The high frequency of carriers of BLM 2281 from
Poland has been noted previously (Shahrabani-Gargir
et al. 1998). In our sample, the highest frequency was
observed in Galicia.
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Table 5
Mutation Frequencies for Other Diseases, by Geographic Region
FREQUENCY OF MUTATION IN
BLM CAN CF FACC
2281 693 854 1282 F508 542 IVS4
Unknown .0108 .0020 .0103 .0104 .0064 .0013 .0064
Mixed AJ .0119 .0012 .0082 .0105 .0068 .0017 .0068
Germany 0 .0025 .0049 .0061 0 .0017 0
CE: .0030 .0023 .0110 .0117 .0085 .0007 .0085
Austria 0 .0010 .0055 .0210 .0010 .0009 .0039
Czech 0 .0029 .0098 .0126 .0050 0 .0065
Hungary .0044 .0030 .0090 .0102 .0086 .0007 .0095
Romania 0 0 .0205 .0136 .0118 .0018 .0015
EE: .0181 .0008 .0107 .0096 .0056 .0010 .0056
Lithuania 0 .0018 .0200 .0081 .0055 .0006 .0114
Poland .0222 .0009 .0109 .0099 .0058 .0012 .0059
Russia .0152 .0002 .0080 .0059 .0054 .0002 .0038
Mediterranean 0 0 0 0 .0085 .0011 0
Mideast 0 0 0 0 0 .0005 0
RESULT FOR MUTATION IN
BLM CAN CF FACC
2281 693 854 1282 F508 542 IVS4
x2 (CE vs. EE) 18.3** 10.3* .1 3.2 9.3* .5 3.3
No. of carriers 135 252 1,467 1,726 1,099 206 856
* .P ! .005
** .4P ! 10
The similar geographic pattern for the LSD and NLSD
mutations argues once again for the primary role of ge-
netic drift or founder effects. Furthermore, for diseases
with multiple mutations, there is no consistent geographic
pattern. For GD, two mutations (1226G and 84GG) are
more common centrally, whereas one (1604) is not; for
TSD, one mutation (1277) is more common centrally, but
the other two (1421 and G269) show the opposite trend.
Similar discordant patterns also exist for CAN and CF.
In tables 4 and 5, the large unknown category approxi-
mately represents a mixture of CE and EE Ashkenazim
comparable to that observed in the geographically defined
sample. When the mutation frequencies in this group are
compared with the CE and EE frequencies for the seven
mutations with significant eastern-central differences, four
are closer to CE, and three are closer to EE. Assuming
that the unknown category is admixed between CE and
EE, with proportion A from CE, we estimated A for each
mutation by the formula ,Ap (p  p )/(p  p )unk EE CE EE
where punk, pCE, and pEE are the observed mutation fre-
quencies in the unknown, CE, and EE groups, respec-
tively. Admixture estimates A for the seven loci range from
28% to 100%, with an average admixture estimate of
63% CE versus 37% EE. These figures are similar to those
observed in the geographically defined sample, in which
there are 53% from CE versus 47% from EE. By contrast,
the mixed AJ group is much more characteristic of EE.
In this group, seven of seven mutations are closer in
frequency to EE than CE, and the admixture estimate
A ranges from 0 to 41%, with an average estimate of
10% CE versus 90% EE. This finding is consistent with
primarily EE Ashkenazi migrations to the countries in-
cluded in this category.
A similar analysis of Germany reveals four mutation
frequencies closer to CE versus three closer to EE. The
average admixture estimate for this group is 68% CE
versus 32% EE. Germany’s position intermediate between
CE and EE likely represents its mix of longer-established
central Ashkenazi founders, as well as more-recent im-
migrants from EE.
Only a few mutations are observed at any frequency
in the Mediterranean or Middle Eastern Jews. The CF
F508 mutation had a Mediterranean frequency of 0.0085,
comparable to the frequencies found in Ashkenazim. Sim-
ilarly, the 542 mutation is found in both Mediterranean
and Mideast groups, whereas the 1282 mutation was re-
stricted to Ashkenazim. These observations are consistent
with earlier data from Israeli Jewish populations (Kerem
et al. 1995). The only other mutation found outside Ash-
kenazim is the GD 1226G mutation, in the Mediterranean
Jews. This observation is not surprising, given its high
frequency and widespread distribution in Europeans in
general, especially in Spain and Portugal (Lacerda et al.
1994). Other AJ mutations have also been found at very
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low frequency in non-Ashkenazi Jews (Peleg et al. 1994).
These most likely represent migrations over the past 1,000
years, although earlier shared origins cannot be excluded.
Discussion
We have shown that no differences exist between LSDs
and NLSDs in the AJ population with respect to (1) num-
ber and frequency of disease mutations, (2) coalescence
times of the various mutations, and (3) the geographic
distribution of mutation frequencies by country/region of
origin in Europe. Thus, there is no evidence that special
selective forces have operated on the LSDs, as compared
with the broad array of other genetic diseases found in
the AJ population.
In addition, we found highly disparate geographic dis-
tributions for mutations within single disease entities—
in particular, GD, TSD, and CAN. Again, these data are
more consistent with random founder effects than with
systematic selection. In particular, three mutations appear
to demonstrate impressive founder effects: BLM 2281,
in Poland/Galicia; GD 84GG, in Hungary/Romania; and
TSD 1421, in Lithuania/Russia.
The results for the TSD 1421 mutation are the most
striking. We observed extreme and highly significant geo-
graphic variation, with a total absence from CE, a fre-
quency of 0.7% in Russia, and a frequency of 1.1% in
Lithuania. This eastern predominance and central ab-
sence is also reflected in the unknown and mixed AJ
groups, in which the mutation frequency in the former
(0.0009), a mostly CE group, is lower than in the latter
(0.0041), a mostly EE group. This pattern is also re-
markably similar to two other AJ mutations: delGAG,
for DYT1 (Risch et al. 1995), and G197del, for FH
(Meiner et al. 1991; Durst et al. 2001). On the basis of
haplotype analysis, both of these mutations were dated
to a coalescence time of 12 generations (range 8–20)
consistent with more-recent founder events in the Lith-
uanian Jewish population (Risch et al. 1995; Durst et
al. 2001). The extreme localization—both in time and
space—observed for the TSD 1421 mutation, as com-
pared with the primary TSD 1277 mutation, along with
the other data reported above, provides compelling ev-
idence for genetic drift and not selection as the expla-
nation for the observed frequency of LSD mutations in
the Ashkenazi population.
Appendix A
Table A1
Diseases and Mutations Included in the Present Analysis
Disease/Gene Mutation(s)
Adenomatous polyposis coli (APC [*175100]) I1307K
Bloom syndrome (BLM [#210900]) 2281(6del,7ins)
Breast cancer:
BRCA1 (*113705) 185delAG
BRCA2 (*600185) 6174delT
Canavan disease (CAN [*271900]) 693(Y231X); 854(E285A)
Cystic fibrosis (CF [#219700]) F508; W1282X
Cystinuria (CSNU [#220100]) 808CrT
Deafness (NSRD1 [#220290]) due to connexin 26 (CX26 [#121011]) 167delT; 35delG
Dysautonomia (DYS [#223900]) IVS20
Factor 11 deficiency (F11 [*264900]) II (E117X); III (F283L)
Familial hypercholesterolemia (FH [#143890]) G197del
Familial hyperinsulinism (HI [#256450]) 3992(GrA)
Fanconi anemia type C (FACC [*227645]) IVS4
Gaucher disease (GD [#230800]) 1226G(N370S); 84GG; 1604(R496H)
Glycogen storage disease VII (GLY7 [*232800]) del5
Mucolipidosis IV (MLIV [#252650]) IVS3
Niemann-Pick disease (NPD [#257200]) L302P
Tay-Sachs disease (TSD [#272800]) 1277(TATC); 1421(IVS12); G269
Torsion dystonia (DYT1 [#128100]) delGAG
NOTE.—Derived from OMIM.
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Electronic-Database Information
Accession numbers and the URL for data presented herein
are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for APC [MIM 175100], BLM
[MIM 210900], BRCA1 [MIM 113705], BRCA2 [MIM
600185], CAN [MIM 271900], CF [MIM 219700], CSNU
[MIM 220100], CX26 [MIM 121011], DYS [MIM 223900],
DYT1 [MIM 128100], FACC [MIM 227645], FH [MIM
143890], F11 [MIM 264900], GD [MIM 230800], GLY7
[MIM 232800], HI [MIM 256450], MLIV [MIM 252650],
NPD [MIM 257200], NSRD1 [MIM 220290], and TSD
[MIM 272800])
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